Latest Prostate cancer Stories
New market research report “Tumor Markers: Innovative Technologies and Emerging Business Opportunities” worked out by Venture Planning Group (VPG) has been recently published by Market Publishers Ltd. According to the study, further development of the tumor marker market will be spurred by the technological advancements in tumor diagnostics and treatment and introduction of new antigens. London, UK (PRWEB) December 24, 2012 Tumor markers form one of the most important segments of the...
Digital Science Press, Inc. announces UroToday.com is expanding editorial content with more indepth clinical education for the urologists and medical oncologists on immunotherapy treatments for men with metastatic castration-resistant prostate cancer (mCRPC). UroToday publishes two year-end review white papers: Best of Prostate and the Best of mCRPC featuring interviews with prostate cancer experts. Berkeley, CA (PRWEB) December 19, 2012 Now in its tenth year as an online urology-medical...
BOTHELL, Wash. and VANCOUVER, British Columbia, Dec. 19, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of PACIFIC, an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in men with metastatic castrate-resistant prostate cancer (CRPC) who are experiencing a rising PSA while receiving Zytiga (abiraterone acetate). The aim of the study is to determine if adding OGX-427 to Zytiga treatment can reverse or delay...
Lawrence LeBlond for redOrbit.com - Your Universe Online More than a decade after the World Trade Center terrorist attack on September 11, 2001, the US government added cancer to the list of sicknesses covered by a $4.3 billion fund set up to help rescue workers and others who were adversely affected by the cleanup process after the tragedy. The health issues were directly related to the dust, debris and fumes released from the twin towers’ wreckage. The addition of cancer to the WTC...
Prostate Research Labs, today announced that their market leading prostate health formula, Prost-P10x®, remains the strongest natural formula available to men looking to support their treatment for prostatitis and CPPS (Chronic Pelvic Pain Syndrome). Irvine, CA (PRWEB) December 18, 2012 Prostatitis is a debilitating disorder that strikes up to 20% of men in the USA and is the 2nd leading cause of visits to a Urologist by men. Non-bacterial prostatitis is generally untreatable with...
NEW YORK, Dec. 18, 2012 /PRNewswire/ -- Sex after prostate cancer was the second most difficult thing to deal with for Canadian men who have or had prostate cancer. Even more difficult was maintaining hope, according to a prostate cancer study commissioned by Astellas Pharma Canada, Inc. and conducted online by Leger Marketing in October 2012. (Photo: http://photos.prnewswire.com/prnh/20121218/NY31740 )...
Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer, and have also developed a compound that inhibits the ability of this molecule to promote the metastatic spread of the cancer. Their study, published in the Dec. 18 online edition of Molecular Cancer Research, is the first to link the enzyme PRSS3 to prostate cancer. "This molecule is a protease, which means it digests other molecules. Our data suggests PRSS3...
BETHESDA, Md., Dec. 17, 2012 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO; NWBOW) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it is scheduled to ring The NASDAQ Stock Market Opening Bell on Tuesday, December 18, 2012 to celebrate the Company's recent financing and up-listing to the NASDAQ Capital Market. NW Bio's common stock and warrants began trading on NASDAQ on December 7, 2012. (Logo:...
ATLANTA, Dec. 17, 2012 /PRNewswire/ -- Elekta has received 510(k) clearance for its Clarity® 4D Monitoring software, enabling U.S. medical centers to implement this new way of reducing the uncertainty caused by prostate motion during radiation treatment. Physicians will be able to monitor the motion of the prostate and surrounding tissues and organs - in real-time and with sub-millimeter accuracy - during the delivery of therapeutic radiation beams. The ability to continuously...
Care improving for colorectal and other cancer patients - but still room for improvement TORONTO, Dec. 17, 2012 /CNW/ - A comprehensive report released today by the Canadian Partnership Against Cancer provides a snapshot of how Canada's cancer system is performing in key areas from prevention through to patient experience and outcomes. Produced in collaboration with cancer programs in each province and territory, the 2012 Cancer System Performance Report is intended to inform...
